Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome
source: pixabay.com

Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome

In a recent press release, biopharmaceutical company Rhythm Pharmaceuticals (“Rhythm”) announced positive data from a Phase 3 clinical trial. During the trial, Rhythm evaluated setmelanotide for patients with Bardet-Biedl syndrome…

Continue Reading Setmelanotide Shows Positive Results in BBS and Alstrom Syndrome
Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients
mcmurryjulie / Pixabay

Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients

According to a publication from EurekAlert, a clinical trial of setmelanotide, an experimental anti-obesity drug, is set to begin soon at the Alberta Diabetes Institute (of the University of Alberta).…

Continue Reading Alberta Diabetes Institute to Study Use of Anti-Obesity Drug in Alström and Bardet-Biedl Patients